A Belgian survey of long-term TOBI® treatment in cystic fibrosis patients  by Penninckx, B. et al.
7. Pulmonology S67
266 A Belgian survey of long-term TOBI® treatment in
cystic ﬁbrosis patients
B. Penninckx1, A. Malfroot2, C. Knoop3, K. De Boeck4, L. Dupont4, F. De
Baets5, K. Desager6, P. Lebecque7, J. Leclercq-Foucart8, G. Casimir9. 1Solvay
Pharma, Brussels, Belgium; 2CF Clinic, UZ Brussel, Belgium; 3CF Clinic, ULB
Hoˆpital Erasme, Belgium; 4CF Clinic, UZ Leuven, Belgium; 5CF Centre, UZ
Gent, Belgium; 6CF Clinic, Antwerp University Hospital, Belgium; 7CF Clinic,
CU Saint-Luc, Belgium; 8CF Clinic, CHR Citadelle Lie`ge, Belgium; 9CF Clinic,
ULB Huderf, Belgium
Tobramycin solution for inhalation (TOBI) is available in Belgium since August
2003 for the treatment of chronic pulmonary infection with Pseudomonas aerugi-
nosa in CF patients aged 6 years and older.
The objectives of this observational study were to survey lung function (expressed
as percentage of FEV1 predicted), exacerbations of respiratory infections, hospital-
izations, and BMI in CF patients on long-term TOBI treatment.
Of the 90 patients included in the analysis, 60% were male and 40% female. The
median age was 23 years (range: 9–46 years), with 80% of the patients being at
least 18 years old. In the adult population, mean BMI stayed around 20 kg/m2
during the survey. In the entire population the mean FEV1 decreased from 62 to
57% during an 18 months treatment period. In the adult population, a decrease was
also observed, from 60 to 58%. The yearly rate of exacerbation was 1.45 for the
entire population and 1.50 for the adult population. In the entire population the
mean number of hospitalizations per year was 0.82 and the mean number of days
per year on IV antibiotics was 8.16. TOBI was stopped in 9 patients (10%), most
frequently because of lung transplantation (3.3%) and airway irritability symptoms
(3.3%).
Conclusion: In a 2-year Belgian survey of CF patients, treatment with TOBI was
well tolerated and appeared to stabilize the lung function decline in the adult
population. Intolerance in a limited number of patients was the most frequent event
leading to treatment stop.
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Objective: To deﬁne the beneﬁt of the new inhalation device Pari eFlow rapid®
in comparison to conventional inhalation devices for basic inhalation therapy with
sodium chloride solutions.
Patients: 53 CF patients participated and 43 completed the study (21 males, mean
age 17.2±9.7 years, range 5–47, mean FEV-1% predicted 80.2±25).
Methods: Prospective, randomized, cross over analysis comparingtwo week periods
of inhalation with (i) conventional device, (ii) Pari eFlow rapid® using the same
volume of inhalation solution, but shorter duration of inhalation, (iii) Pari eFlow
rapid® using the same duration of inhalation therapy, but increased volume of
salt solution. Primary outcome was improvement of FEV-1% predicted of daily
lung function testing with an ambulatory spirometry (Micro DL, Viasys, Germany)
compared to one week run-in baseline.
Results: Compared to baseline, mean FEV-1% was the same when the conventional
inhalation device was used (80.6±25). FEV-1% was higher if Pari eFlow rapid®
was used with the same volume (82.9±25, p = 0.032) and was best if Pari eFlow
rapid® was used with the same duration of inhalation therapy as with standard
device therapy (83.3±26, p = 0.001). In the later case inhalation solution volume
was increased by a mean of 269%. Mean patient satisfaction considering subjective
efﬁcacy was better with the Pari eFlow rapid® [scale from 1: best to 6: worst:
(i) 2.31, (ii) 1.87, (iii) 1.94].
Conclusion: Efﬁcacy of basic inhalation therapy can be improved using inhalation
devices which generate a larger aerosol output per time. Best effects can be obtained
if inhalation time is not diminished but the amount of inhalation solution is increased
instead.
Supported by: cf-initiative-aktiv e.V. Mu¨nchen.
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Improvements in survival and reduction in lung function decline for patients with CF
has led to consideration of novel trial endpoints, including quality of life (QoL).
Methods: 209 CF patients from 5 CF centres were recruited. The CFQ was
applied to children (children & parent administered) and adolescents/adults (self-
administered).
Aim: Determine QoL in people with CF recruited to a multicentre trial, using a
CF QoL tool (CFQ) (Quittner 2003).
We determined: 1) the relationship between child and parent administered CFQ
tools during stability and 2) if QoL was related to markers of CF severity.
Results: 1) Seven domains were applied to children (child & parent administered).
In two domains parental response was lower than child response (treatment &
eating), two domains were higher (respiratory & digestion), and three were similar.
Scores for each of the domains for children were similar to the published literature.
2) FEV1% pred in children was related to respiratory & eating domains (r = 0.38–
0.43, p< 0.001), and in adolescents/adults related to physical, role, vitality, health &
respiratory domains (r = 0.27−0.58, p< 0.001). CRP in children was negatively
related to the respiratory domain (r = −0.43, p = 0.002), & in adolescent/adult
patients to physical, vitality, eating, health, weight & respiratory domains (r = −0.16
to −0.36, p< 0.05).
Conclusions: Parents & their children do not have the same perception for all QoL
domains. Domains of CFQ in older people with CF are correlated with markers of
disease severity & to a lesser extent in children.
Supported by: ACFRT, Pﬁzer Aus.
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The aim of this study was to assess the impact of inhalation therapy duration
on treatment adherence and quality of life among CF patients. The eFlow™ was
selected thing that it is customized to be more rapid and efﬁcient in pulmonary
drug delivered compared to current nebulizer systems.
Methods: Seventeen patients with CF were enrolled to evaluate the new electronic
inhaler during one month. Patient perception and adherence to the eFlow™
were assessed using CFQ14 questionnaire at the beginning and end of the trial.
Recordings of FCV and FEV1 were collected at the beginning and after one month
of treatment.
Results: 17 patients completed survey (9 female and 8 male), mean age 17.5
range 7.6−29.2 years. The end of trial questionnaire showed an increased patient’s
adherence to eFlow™ system (−0.97 forgetting by month). Indeed, among 17
patients, 8 increased signiﬁcantly adherence (p< 0.05). Time spent for nebulization
decreased: mean 15 minutes ±5 minutes and not offset by preparation time.
Quality of life linked to treatment constraints increased 72.3 vs 62 (p< 0.005).
The difference is sufﬁcient to be felt by patient.
Conclusion: treatments constraints improvement increased adherence and quality
of life. Other factors contribute towards adherence: the effect felt, understanding
of the disease and the principle of action of medication. It’s essential to better
understand the factors of compliance to treatment in chronic diseases in order to
improve the care of patients. The simpliﬁcation of delivery procedures is important
as therapeutic education of patients to improve treatment adherence.
